Linceis Capital

Linceis Capital is a Canadian public company that appears to function primarily as a biotech-focused holding or acquisition vehicle rather than an operating drug developer with a disclosed in-house pipeline. Public disclosures indicate it was spun out of Advanced Proteome Therapeutics in 2023 and holds a large equity position in Advanced Proteome Therapeutics. In May 2024, DiaGen AI announced a letter of intent to merge with Linceis Capital, positioning the combined company around generative artificial intelligence for protein design, drug discovery, diagnostics, health, wellness, longevity, and precision medicine. Available public information does not show a clearly disclosed, independently branded therapeutic pipeline for Linceis itself. As a result, the company is best characterized as an active public biotech capital/transaction vehicle with healthcare exposure through its holdings and proposed combination activity.